Dr. Gabriel C Choi, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 740 Solano St, Corning, CA 96021 Phone: 408-480-2491 |
Abhishek Chaudhary Dentist Medicare: Not Enrolled in Medicare Practice Location: 740 Solano St, Corning, CA 96021 Phone: 661-665-0080 |
Dr. Joseph Olufemi Fagbamigbe Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 705 East St, Corning, CA 96021 Phone: 530-900-7550 |
Dr. Dario Abramo Sartori, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 480 Solano St, Corning, CA 96021 Phone: 530-824-5165 |
John Kempton Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 155 Solano St, Corning, CA 96021 Phone: 530-824-4663 |
Dr. Richard Bond Dunbar, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1904 Solano St, Corning, CA 96021 Phone: 530-824-5701 Fax: 530-824-2020 |
Dr. Shu Yunn Law, BDS, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 740 Solano St, Corning, CA 96021 Phone: 530-690-2778 |
News Archive
The emerging field of "personalized" or "precision" medicine holds great promise in the fight against cancer. If scientists can identify the genetic changes that drive each patient's cancer cells, they can use that information to develop targeted treatments. But achieving this goal will require massive amounts of genomic and clinical data and a sophisticated infrastructure to manage and analyze the data.
Researchers at The University of Texas Medical Branch have determined that maternal exposure to high levels of flame-retardants may be a contributing factor in preterm births.
Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant.
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.
President Donald Trump tried to change the subject from his impeachment investigation by going to Florida to unveil changes to the Medicare program before an audience of seniors.
› Verified 9 days ago